Cargando…

Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine

Coronavirus disease 2019 (COVID-19) is a disease characterized by predominantly respiratory symptoms, which can progress to respiratory failure. Due to the novelty of the vaccines, it is difficult to assess if there are any associated long-term side effects. Here, we present a case of an elderly fem...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Edward, Bae, Suhwoo, Vaysblat, Michael, Abdelwahed, Mohammed, Sarkar, Kumar, Bae, Stewart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184721/
https://www.ncbi.nlm.nih.gov/pubmed/37197108
http://dx.doi.org/10.7759/cureus.37612
_version_ 1785042199968219136
author Bae, Edward
Bae, Suhwoo
Vaysblat, Michael
Abdelwahed, Mohammed
Sarkar, Kumar
Bae, Stewart
author_facet Bae, Edward
Bae, Suhwoo
Vaysblat, Michael
Abdelwahed, Mohammed
Sarkar, Kumar
Bae, Stewart
author_sort Bae, Edward
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a disease characterized by predominantly respiratory symptoms, which can progress to respiratory failure. Due to the novelty of the vaccines, it is difficult to assess if there are any associated long-term side effects. Here, we present a case of an elderly female who received the Moderna COVID-19 vaccine and developed a high-grade sarcoma at the site of the injection. A 73-year-old female with a past medical history of hypertension, hyperlipidemia, and renal angiomyolipoma status post resection in 2019 presented with worsening right upper arm swelling for the past two weeks. She noticed the swelling two to four days after receiving her second dose of the Moderna vaccine within 1 cm from the prior injection site. Physical examination was remarkable for a 6 cm, circular, mobile, soft mass present in the right upper arm. MRI with and without contrast revealed a 5.2 cm soft tissue mass overlying the triceps region with irregular features concerning for malignancy. Fine needle aspiration revealed pathologic characteristics indicative of high-grade sarcoma. The patient ultimately had resection of the mass four months after the initial visit and was diagnosed as having grade 3, stage IIIA undifferentiated, pleomorphic high-grade sarcoma. Herein, we present a case demonstrating the development of high-grade sarcoma at the injection site in an elderly female patient within days of receiving the second dose of the Moderna COVID-19 vaccine. Currently, it is unclear whether there is a true association between the vaccines and malignancy or inflammatory response exacerbating underlying malignancy. This case highlights the necessity to investigate and be aware of such rare, adverse complications that may be associated with the novel COVID-19 vaccinations to guide physicians in their differential diagnosis.
format Online
Article
Text
id pubmed-10184721
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101847212023-05-16 Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine Bae, Edward Bae, Suhwoo Vaysblat, Michael Abdelwahed, Mohammed Sarkar, Kumar Bae, Stewart Cureus Internal Medicine Coronavirus disease 2019 (COVID-19) is a disease characterized by predominantly respiratory symptoms, which can progress to respiratory failure. Due to the novelty of the vaccines, it is difficult to assess if there are any associated long-term side effects. Here, we present a case of an elderly female who received the Moderna COVID-19 vaccine and developed a high-grade sarcoma at the site of the injection. A 73-year-old female with a past medical history of hypertension, hyperlipidemia, and renal angiomyolipoma status post resection in 2019 presented with worsening right upper arm swelling for the past two weeks. She noticed the swelling two to four days after receiving her second dose of the Moderna vaccine within 1 cm from the prior injection site. Physical examination was remarkable for a 6 cm, circular, mobile, soft mass present in the right upper arm. MRI with and without contrast revealed a 5.2 cm soft tissue mass overlying the triceps region with irregular features concerning for malignancy. Fine needle aspiration revealed pathologic characteristics indicative of high-grade sarcoma. The patient ultimately had resection of the mass four months after the initial visit and was diagnosed as having grade 3, stage IIIA undifferentiated, pleomorphic high-grade sarcoma. Herein, we present a case demonstrating the development of high-grade sarcoma at the injection site in an elderly female patient within days of receiving the second dose of the Moderna COVID-19 vaccine. Currently, it is unclear whether there is a true association between the vaccines and malignancy or inflammatory response exacerbating underlying malignancy. This case highlights the necessity to investigate and be aware of such rare, adverse complications that may be associated with the novel COVID-19 vaccinations to guide physicians in their differential diagnosis. Cureus 2023-04-15 /pmc/articles/PMC10184721/ /pubmed/37197108 http://dx.doi.org/10.7759/cureus.37612 Text en Copyright © 2023, Bae et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Bae, Edward
Bae, Suhwoo
Vaysblat, Michael
Abdelwahed, Mohammed
Sarkar, Kumar
Bae, Stewart
Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine
title Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine
title_full Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine
title_fullStr Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine
title_full_unstemmed Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine
title_short Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine
title_sort development of high-grade sarcoma after second dose of moderna vaccine
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184721/
https://www.ncbi.nlm.nih.gov/pubmed/37197108
http://dx.doi.org/10.7759/cureus.37612
work_keys_str_mv AT baeedward developmentofhighgradesarcomaafterseconddoseofmodernavaccine
AT baesuhwoo developmentofhighgradesarcomaafterseconddoseofmodernavaccine
AT vaysblatmichael developmentofhighgradesarcomaafterseconddoseofmodernavaccine
AT abdelwahedmohammed developmentofhighgradesarcomaafterseconddoseofmodernavaccine
AT sarkarkumar developmentofhighgradesarcomaafterseconddoseofmodernavaccine
AT baestewart developmentofhighgradesarcomaafterseconddoseofmodernavaccine